Project Grant K08CA296776
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$139K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $181,640 to The University of Texas MD Anderson Cancer Center to conduct research on using liquid biopsy biomarkers, including circulating tumor DNA (ctDNA) and extracellular vesicle RNA (evRNA), to evaluate immunotherapy response in patients with colorectal and anal cancers. The principal investigator will leverage this funding to expand on their leadership of several...
This $1,449,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to study the fundamental regulation of extrachromosomal DNA (ecDNA) in cancer genomes. The project aims to develop new live-cell chromatin labeling strategies and integrate advanced imaging, synthetic genome engineering, and optical/genetic perturbation to systematically investigate how ecDNA orchestrates massive...
This $125,783 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) supports a research project to investigate the mechanisms of CDH1-inactivated advanced gastric adenocarcinoma (GAC) progression. The University of Texas MD Anderson Cancer Center, the award recipient, aims to determine the intrinsic (SOX4 and EZH2 mediated) and extrinsic (immune evasion) dysregulation mechanisms underlying CDH1 loss in advanced GAC. The research...
This $128,936 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research by the University of Texas MD Anderson Cancer Center focused on investigating the initiation and progression of esophageal squamous cell carcinoma (ESCC). The research aims to elucidate the cellular and genetic mechanisms underlying ESCC development, including the role of preneoplastic cells and epithelial-mesenchymal plasticity in immune evasion....
This Project Grant award of $427,095 from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program will fund the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The goal is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing; Investigate spatiotemporal interaction...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $645,873 to The University of Texas MD Anderson Cancer Center to develop an innovative in vivo approach for generating chimeric antigen receptor (CAR) macrophages targeting the epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma immunotherapy. The 5-year project, beginning in July 2024, aims to evaluate the dynamics, safety, transcriptional profiles, and...
The National Institutes of Health's National Cancer Institute (NCI) awarded a $187,887 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University. The 5-year grant, starting February 1, 2025, will support research on the role of extrachromosomal DNA (ecDNA) in HER2-amplified breast cancer. The project aims to investigate how HER2 ecDNA contributes to genome instability, treatment resistance, and breast cancer pathogenesis. It will use...
The National Cancer Institute (NCI) awarded a $160,642 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The award, effective August 7, 2024 through January 31, 2026, aims to develop novel epigenome editing technologies and identify genes involved in chimeric antigen receptor (CAR) T cell exhaustion. The research will create split-engineered...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $1,384,482 over 5 years to the University of Texas MD Anderson Cancer Center to investigate the role of bacterial DNA methyltransferases in cancer development and progression. The key objectives are to: Determine if the DNA methyltransferase enzyme M.FNI from the bacteria Fusobacterium nucleatum contributes to pathoadaptation of this microbe in the tumor...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) provides $606,635 to The University of Texas MD Anderson Cancer Center to investigate how the transcription factor BHLHE40 regulates the anti-tumor effector functions of CD4 and CD8 T cells during cancer immunotherapies such as immune checkpoint inhibitor therapy and neoantigen cancer vaccines. The 5-year project, beginning June 1, 2024, seeks to determine how cell-specific...